GSE206931 WDR5 inhibition WIN 3 v 2 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE206931_WDR5 inhibition_WIN_3_v_2_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE206931_WDR5 inhibition_WIN_3_v_2_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE206931_WDR5 inhibition_WIN_3_v_2_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE206931_WDR5 inhibition_WIN_3_v_2_human_up.

Results found

Linked to

 

Label

Description

 

Gene

AMZ2 pseudogene 1

Gene

long intergenic non-protein coding RNA 910

Gene

PPP3CB antisense RNA 1

Gene

ZNF710 antisense RNA 1

Gene

NDUFA6 divergent transcript

Gene

SAP30L and GALNT10 antisense RNA 1

Gene

long intergenic non-protein coding RNA 1569

Gene

SOD2 overlapping transcript 1

Gene

chromosome 3 putative open reading frame 36

Gene

MYO1D divergent transcript

  • Gene

    AMZ2 pseudogene 1


  • Gene

    long intergenic non-protein coding RNA 910


  • Gene

    PPP3CB antisense RNA 1


  • Gene

    ZNF710 antisense RNA 1


  • Gene

    NDUFA6 divergent transcript


  • Gene

    SAP30L and GALNT10 antisense RNA 1


  • Gene

    long intergenic non-protein coding RNA 1569


  • Gene

    SOD2 overlapping transcript 1


  • Gene

    chromosome 3 putative open reading frame 36


  • Gene

    MYO1D divergent transcript

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.